ATP 152
Alternative Names: ATP-152Latest Information Update: 04 Jun 2023
At a glance
- Originator Amal Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Adenocarcinoma
Most Recent Events
- 14 May 2023 ATP 152 is available for licensing as of 01 May 2023. https://www.amaltherapeutics.com/partnering
- 13 Mar 2023 Phase-I clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral) (NCT05846516)
- 13 Mar 2023 Phase-I clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT05846516)